Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left ...

Noureddin et al. (2024). Clin Gastroenterol Hepatol, 22(12), 2367-2377. (*consistent with stages F2 to F3 fibrosis, also referred to in the literature as "MASH with significant fibrosis," "MASH ...

In January 2024, Sagimet announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis ...

A ≥1-stage improvement in fibrosis was seen in 17.5%, 29.2% and 40.9% of patients (F2-F3) in the placebo, 300 mg and 600 mg arms respectively. The publication also highlights the broad ...

In October 2024, Sagimet announced that the FDA granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent ...